Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fentanyl is a highly potent synthetic opioid analgesic of the 4-anilinopiperidine class. It acts primarily as a strong agonist at the mu-opioid receptor in the central nervous system. Fentanyl is approximately 50 to 100 times more potent than morphine and about 30 to 50 times more potent than heroin. It was first synthesized in 1960 by Belgian pharmacologist Paul Janssen and introduced for medical use in Europe in the mid-1960s and approved in the United States in 1968[2][6][8]. Medically, fentanyl is used for managing severe pain (such as cancer pain or post-surgical pain) that does not respond well to other opioids. Its high potency also makes it a major drug of abuse with significant risk of overdose and death due to respiratory depression[3][7][10]. Fentanyl is available as injectable formulations, transdermal patches, sublingual tablets/lozenges/buccal films, and nasal sprays[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fentanyl.